Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients
American Journal of Clinical Oncology, 10/06/09

Paluch-Shimon S et al. – Our results suggest an important role for HR expression in modulating metastases predilection and disease progression in HER2-positive breast cancer.

Methods

Retrospective analysis of consecutive metastatic HER2-positive breast cancer patients conducted in 2 medical centers
Associations between hormone receptors expression and clinical variables, and metastatic spread pattern and survival studied

Results

Study population included 137 metastatic HER2-positive breast cancer patients, 56 were HR-positive and 81 HR-negative
No significant differences between 2 groups found for demographic and clinical characteristics, including age, stage at diagnosis, tumor histology, and grade
Similar response rate to trastuzumab observed in both study groups
Significantly, longer, median, disease-free, and overall survival noted among HR-positive patients
Patients in HR-negative group had significantly more liver metastases, a trend for more brain metastases, and less bone metastases
Strong trend for more visceral metastases in HR-negative group

<< Previous
Identifying Patients in Financial Need

Next >>
Weekly paclitaxel and trastuzumab as a first-line therapy in...